
September 21, 2010
Phenex receives 6 M Euro (7,8 M USD) in its Series C financing round
The Nuclear Receptor specialist company invests additional money into its R&D programs in NASH (FXR)…
Waldhofer Str. 104
69123 Heidelberg, Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com
Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a research site in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.